CrestOptics selected by Akoya Biosciences for spatial biology collaboration

  • CrestOptics will provide spinning disk microscopy technology to enhance the detection and performance of single-cell, multiplex imaging
  • CrestOptics’ instruments will be integrated with Akoya’s CODEX® system through Akoya’s Imaging Innovators (I2) Network to offer new imaging solutions to researchers
  • Collaboration aims to provide new workflows, faster acquisition speeds and deeper resolution

Rome, IT, 29 June 2021: CrestOptics S.p.A., a manufacturer of high-end microscopy solutions and advanced systems for fluorescence microscopy and diagnostic applications, today announced that it has been selected by Akoya Biosciences Inc., (Nasdaq: AKYA) The Spatial Biology Company®, as a premier microscope provider to jointly develop new spatial biology and spatial phenotyping applications. CrestOptics has been invited to the partnership among other leading companies in the field of imaging and diagnostics to support Akoya’s Imaging Innovators (I2) Network.

 

“We are focused on developing versatile systems for a variety of applications to support researchers in the cell biology and imaging space, and are excited to be a part of this innovative collaboration to expand imaging capabilities for life sciences,” said Renato Giacobbo Scavo, CEO of CrestOptics.

 

“CrestOptics’ high-end instruments, such as our spinning disk confocal, can be paired directly to Akoya’s CODEX system for single-cell multiplex imaging enabling high resolution, large field of view, and fast 3D imaging to support researchers in this field of study,” said Alessandra Scarpellini, PhD, Head of Sales and Marketing at CrestOptics.

 

“Collaborating with leading imaging companies, including CrestOptics,will help accelerate further innovation in the field of spatial biology to provide faster and more precise tools for biological discoveries,” said Brian McKelligon, President and CEO of Akoya Biosciences. “By working together with partners we can further expand our CODEX system with the latest and most advanced microscopy platforms to streamline the user experience, add new workflows, accelerate acquisitions speeds, and provide deeper resolution.”

 

CrestOptics manufactures high-end microscopy instruments under own brand and as an original equipment manufacturer (OEM). The Company’s instrumentation can be integrated with other high-end imaging systems used in life science research to enhance detection and performance of imaging.

About Akoya Biosciences Inc. 

As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and treatment response. Akoya offers two distinct solutions, the CODEX® and Phenoptics™ platforms, to serve the diverse needs of researchers across discovery, translational and clinical research. For more information, please visit www.akoyabio.com/.

 

Akoya Bioscences Inc. Forward Looking Statements

This press release contains “forward-looking statements” under applicable securities laws. In some cases, such statements can be identified by words such as: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements include express or implied statements regarding our ability to achieve our business strategies, growth, or other future events or conditions. Such statements are based on our current beliefs, expectations, and assumptions about future events or conditions, which are subject to inherent risks and uncertainties, including the risks and uncertainties discussed in the filings we make from time to time with the Securities and Exchange Commission. Actual results may differ materially from those indicated in forward-looking statements, and you should not place undue reliance on them. All statements herein are based only on information currently available to us and speak only as of the date hereof. Except as required by law, we undertake no obligation to update any such statement.

Share this Article
Share on linkedin
Share on facebook
Share on twitter
Share on whatsapp
Share on email